Brian Halevie-Goldman
Psychiatry · Fairfield, CANPI 1669694857
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 842 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 842 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$3K
- Alkermes, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Vanda Pharmaceuticals Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $8K from 20 others
What the payments were for
- Food & beverage$21,17793%
- Education$1,5077%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 97 | $3,282 |
| Alkermes, Inc. | 75 | $2,594 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 83 | $2,486 |
| AbbVie(2 entities) | 146 | $2,432 |
| Vanda Pharmaceuticals Inc. | 74 | $1,876 |
| Takeda Pharmaceuticals U.S.A., Inc. | 95 | $1,685 |
| Lundbeck LLC | 61 | $1,301 |
| Pinnacle, Inc | 1 | $1,200 |
| E.r. Squibb & Sons, L.L.C. | 21 | $788 |
| Bausch Health US, LLC | 41 | $749 |
| Johnson & Johnson | 13 | $731 |
| Teva Pharmaceuticals USA, Inc. | 20 | $718 |
| Axsome Therapeutics, Inc. | 11 | $527 |
| Neurocrine Biosciences, Inc. | 22 | $447 |
| Sunovion Pharmaceuticals Inc. | 22 | $423 |
| Avanir Pharmaceuticals, Inc. | 18 | $365 |
| Acadia Pharmaceuticals Inc | 3 | $228 |
| Merck | 10 | $191 |
| Ironshore Pharmaceuticals Inc. | 6 | $184 |
| Supernus Pharmaceuticals, Inc. | 9 | $165 |
| Jazz Pharmaceuticals Inc. | 4 | $125 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Corium, LLC | 2 | $48 |
| Acella Pharmaceuticals, LLC | 2 | $43 |
| Shire North American Group Inc | 2 | $25 |
| Tris Pharma Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,932
- REXULTI$1,071
- ARISTADA$930
- VRAYLAR$492
- Auvelity$370
- ABILIFY MAINTENA$368
- Fanapt$362
- CAPLYTA$358
- INVEGA SUSTENNA$295
- ABILIFY ASIMTUFII$244
- SPRAVATO$238
- ARISTADA INITIO$233
- COBENFY$217
- INVEGA TRINZA$146
- Jornay PM 20mg capsules (Bottle of 100)$125
- AJOVY$123
- NUPLAZID$109
How this compares
$22,684 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 26 | $94,488 |
| LybalviOlanzapine/Samidorphan Malate | 25 | $41,476 |
| CaplytaLumateperone Tosylate | 23 | $37,071 |
| Lisdexamfetamine Dimesylate | 26 | $6,830 |
| Risperidone OdtRisperidone | 13 | $6,633 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,264 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $5,496 |
| BelsomraSuvorexant | 12 | $5,222 |
| Asenapine Maleate | 25 | $4,320 |
| Ziprasidone Hcl | 64 | $2,651 |
| Quetiapine Fumarate | 103 | $2,109 |
| Clomipramine Hcl | 49 | $1,883 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 20 | $1,831 |
| Fluvoxamine Maleate | 30 | $1,430 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $1,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $731 | $94,48826 claims |
| Alkermes, Inc.Lybalvi | $2,594 | $41,47625 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,486 | $37,07123 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,685 | $11,76025 claims |
| MerckBelsomra | $191 | $5,22212 claims |
| AbbVieArmour Thyroid | $2,432 | $60512 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $43 | $39011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Fairfield
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.